Effect of Aripiprazole and Risperidone in Improving Obsessive-compulsive symptoms in Bipolar patients

Comparison of the Effectiveness of Aripiprazole and Risperidone in Improving Obsessive-compulsive symptoms in Bipolar patients Comorbid Obsessive-compulsive disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170716035117N1

Enrollment

Registered

2018-01-01

Start date

2017-07-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Obsessive-compulsive disorder. Condition 2: Bipolar disorder. Obsessive-compulsive disorder Bipolar disorder

Interventions

Intervention 1: First intervention group: In addition to peptic stabilizers, aripiprazole is started at a dose of 2.5 mg and gradually administered to the end of the second week to 10 mg per day. The

Treatment - Drugs

First intervention group: In addition to peptic stabilizers, aripiprazole is started at a dose of 2.5 mg and gradually administered to the end of the second week to 10 mg per day. The duration of use

Intervention group2:In addition to mood stabilizers, Risperidone was started by 1 mg and gradually received 2 mg / day until the end of the first week.Duration of use is 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: age between 18 and 65 years A definitive diagnosis of Bipolar disorder with Obsessive-compulsive disorder based on DSM-5 criteria Bipolar patients in Maintenance phase Patients with ability to answer and evaluate with Yale Brown scale (Higher education level) Patients with Yale-Brown Obsessive-Compulsive Scale 16 or higher

Exclusion criteria

Exclusion criteria: Acute and severe physical illness during study Presence of unsafe pregnancy prevention method in women of reproductive age Pregnancy Bearst feeding Substance abuse and alcohol abuse in the six months before study Accompanied with other psychiatric disorders

Design outcomes

Primary

Measure	Time frame
Severity obsessive compulsion. Timepoint: The beginning of the study and every four weeks until the twelfth week. Method of measurement: Yale Brown Obsessive-Compulsion Scale.	—

Secondary

Measure	Time frame
The onset of side effects of drugs. Timepoint: Weeks four, eighth, twelfth. Method of measurement: Clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemesadat Qoreishi

Kashan University of Medical Sciences

dr.zoghoreishi@yahoo.com+98 31 5554 9111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026